Holen Sie sich die Stockscreener-App
10.25
0.58%
-0.06
Handel nachbörslich:
10.33
0.08
+0.78%
Schlusskurs vom Vortag:
$10.31
Offen:
$10.43
24-Stunden-Volumen:
6.49M
Relative Volume:
1.10
Marktkapitalisierung:
$2.38B
Einnahmen:
$510.17M
Nettoeinkommen (Verlust:
$146.93M
KGV:
17.11
EPS:
0.599
Netto-Cashflow:
$27.51M
1W Leistung:
-5.96%
1M Leistung:
+11.53%
6M Leistung:
-33.31%
1J Leistung:
-56.77%
1-Tages-Spanne:
$10.05
$10.56
1-Wochen-Bereich:
$10.05
$10.88
52-Wochen-Spanne:
$7.2101
$23.98
Adma Biologics Inc Stock (ADMA) Company Profile
Firmenname
Adma Biologics Inc
Sektor
Branche
Telefon
(201) 478-5552
Adresse
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
10.25 | 2.40B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | Fortgesetzt | Raymond James | Strong Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2021-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Eingeleitet | Jefferies | Buy |
| 2019-04-15 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-12-11 | Bestätigt | Maxim Group | Buy |
| 2017-11-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2016-08-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-07-25 | Bestätigt | Maxim Group | Buy |
| 2015-05-13 | Bestätigt | Maxim Group | Buy |
| 2014-12-08 | Eingeleitet | Oppenheimer | Outperform |
| 2014-12-01 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth? - Yahoo Finance
CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weighing ADMA Biologics (ADMA) After A 56% One-Year Share Price Decline - Yahoo Finance
Assessing ADMA Biologics (ADMA) Valuation As Securities Investigations Follow Channel Stuffing Allegations - Yahoo Finance
ADMA Secures FDA Approval for Asceniv Expansion - GuruFocus
ADMA Biologics’ ASCENIV Receives FDA Approval to Treat Pediatric Immunodeficiency Patients Aged 2 and Older - Minichart
ADMA Biologics Receives FDA Approval to Expand Asceniv Label for Pediatric Patients - Moomoo
ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label - TipRanks
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older - The Manila Times
Children as young as 2 gain access to ADMA's ASCENIV after FDA approval - Stock Titan
[8-K] ADMA BIOLOGICS, INC. Reports Material Event - Stock Titan
ADMA Biologics Announces FDA Approval to Expand the Label - GlobeNewswire
$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% - GlobeNewswire
BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - GlobeNewswire Inc.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ... - Caledonian Record
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Report And Legal Investigation - Sahm
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - PR Newswire
MSN Money - MSN
Earnings Preview: ADMA to Report Financial Results Post-market on May 06 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ... - Caledonian Record
ADMA stock downgraded by Cantor as ‘channel stuffing’ claims shake investor confidence - MSN
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vanguard (NASDAQ: ADMA) reports 12.11M shares, 5.08% stake - Stock Titan
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Immunoglobulin Market Leading Players AnalysisADMA - openPR.com
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
Investigation into ADMA Biologics for Potential Securities Fraud - Intellectia AI
ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Research - MarketBeat
ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday - MarketBeat
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA ... - Caledonian Record
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Yahoo Finance
ADMA Biologics Investor News: If You Have Suffered Losses - GlobeNewswire
ADMA Biologics rejects claims made in short-seller report - MSN
ADMA Biologics drops amid short report from Culper Research - MSN
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
Q2 2025 ADMA Biologics Inc Earnings Call Transcript - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: Could an 83% Potential Upside Be Within Reach? - DirectorsTalk Interviews
Calamos Advisors LLC Increases Stock Position in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics gains after refuting short seller claims - MSN
Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA) - Yahoo Finance
Does ADMA Biologics' growth story outweigh short-seller concerns? - MSN
ADMA stock drops 6% after Culper Research alleges channel stuffing - MSN
Down 27% in 4 weeks, here's why Adma Biologics (ADMA) looks ripe for a turnaround - MSN
Wall Street Zen Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy - MarketBeat
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
Finanzdaten der Adma Biologics Inc-Aktie (ADMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):